|
1
|
Janowska M, Potocka N, Paszek S, Skrzypa M, Żulewicz K, Kluz M, Januszek S, Baszuk P, Gronwald J, Lubiński J, Zawlik I, Kluz T. An Assessment of GPX1 (rs1050450), DIO2 (rs225014) and SEPP1 (rs7579) Gene Polymorphisms in Women with Endometrial Cancer. Genes (Basel) 2022; 13:genes13020188. [PMID: 35205233 PMCID: PMC8871918 DOI: 10.3390/genes13020188] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 01/14/2022] [Accepted: 01/17/2022] [Indexed: 02/01/2023] Open
Abstract
Background: Numerous studies indicate a relationship between the presence of GPX1 (rs1050450), DIO2 (rs225014) and SEPP1 (rs7579) gene polymorphisms and the development of chronic or neoplastic diseases. However, there are no reports on the influence of these polymorphisms on the development of endometrial cancer. Methods: 543 women participated in the study. The study group consisted of 269 patients with diagnosed endometrial cancer. The control group consisted of 274 healthy women. Blood samples were drawn from all the participants. The PCR-RFLP method was used to determine polymorphisms in the DIO2 (rs225014) and GPX1 (rs1050450) genes. The analysis of polymorphisms in the SEPP1 (rs7579) gene was performed by means of TaqMan probes. Results: There was a 1.99-fold higher risk of developing endometrial cancer in CC homozygotes, DIO2 (rs225014) polymorphism (95% Cl 1.14–3.53, p = 0.017), compared to TT homozygotes. There was no correlation between the occurrence of GPX1 (rs1050450) and SEPP1 (rs7579) polymorphisms and endometrial cancer. Conclusion: Carriers of the DIO2 (rs225014) polymorphism may be predisposed to the development of endometrial cancer. Further research confirming this relationship is recommended.
Collapse
Affiliation(s)
- Magdalena Janowska
- Department of Gynecology and Obstetrics, Fryderyk Chopin University Hospital No. 1, 35-055 Rzeszow, Poland; (M.J.); (S.J.); (T.K.)
| | - Natalia Potocka
- Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, College of Medical Sciences, University of Rzeszow, 35-959 Rzeszow, Poland; (N.P.); (S.P.); (M.S.); (K.Ż.)
| | - Sylwia Paszek
- Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, College of Medical Sciences, University of Rzeszow, 35-959 Rzeszow, Poland; (N.P.); (S.P.); (M.S.); (K.Ż.)
| | - Marzena Skrzypa
- Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, College of Medical Sciences, University of Rzeszow, 35-959 Rzeszow, Poland; (N.P.); (S.P.); (M.S.); (K.Ż.)
| | - Kamila Żulewicz
- Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, College of Medical Sciences, University of Rzeszow, 35-959 Rzeszow, Poland; (N.P.); (S.P.); (M.S.); (K.Ż.)
| | - Marta Kluz
- Department of Pathology, Fryderyk Chopin University Hospital No. 1, 35-055 Rzeszow, Poland;
| | - Sławomir Januszek
- Department of Gynecology and Obstetrics, Fryderyk Chopin University Hospital No. 1, 35-055 Rzeszow, Poland; (M.J.); (S.J.); (T.K.)
| | - Piotr Baszuk
- Department of Genetics and Pathology, Pomeranian Medical University, 70-204 Szczecin, Poland; (P.B.); (J.G.); (J.L.)
| | - Jacek Gronwald
- Department of Genetics and Pathology, Pomeranian Medical University, 70-204 Szczecin, Poland; (P.B.); (J.G.); (J.L.)
| | - Jan Lubiński
- Department of Genetics and Pathology, Pomeranian Medical University, 70-204 Szczecin, Poland; (P.B.); (J.G.); (J.L.)
| | - Izabela Zawlik
- Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, College of Medical Sciences, University of Rzeszow, 35-959 Rzeszow, Poland; (N.P.); (S.P.); (M.S.); (K.Ż.)
- Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, 35-959 Rzeszow, Poland
- Correspondence:
| | - Tomasz Kluz
- Department of Gynecology and Obstetrics, Fryderyk Chopin University Hospital No. 1, 35-055 Rzeszow, Poland; (M.J.); (S.J.); (T.K.)
- Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, 35-959 Rzeszow, Poland
| |
Collapse
|
|
2
|
Association of GSTP1 p.Ile105Val (rs1695, c.313A > G) Variant with the Risk of Breast Carcinoma among Egyptian Women. Biochem Genet 2021; 59:1487-1505. [PMID: 33939082 DOI: 10.1007/s10528-021-10070-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Accepted: 04/19/2021] [Indexed: 01/01/2023]
Abstract
Several reports examined the association of the GSTP1 p.Ile105Val (rs1695, c.313A > G) variant with the elevated risk of multiple cancerous diseases involving breast carcinoma, but with inconclusive findings. The primary purpose of this study is to test the association of this essential variant with the risk of breast carcinoma among Egyptian females. This case-control study was conducted based on 200 participants involving 100 women diagnosed with breast carcinoma and 100 unrelated cancer-free controls from the same district. The genomic DNA for all participants was genotyped utilizing T-ARMS-PCR procedure. The frequencies of the GSTP1 p.Ile105Val (rs1695, c.313A > G) variant indicated a statistically significant with the elevated risk of breast carcinoma under various genetic models, including allelic (OR = 2.48, P-value < 0.001) and dominant (OR = 2.36, P-value = 0.003) models. In conclusion, the GSTP1 p.Ile105Val (rs1695, c.313A > G) variant was considered as an independent risk factor for breast carcinoma among Egyptian women.
Collapse
|
|
3
|
Wang P, Zhu Y, Xi S, Li S, Zhang Y. Association between MnSOD Val16Ala Polymorphism and Cancer Risk: Evidence from 33,098 Cases and 37,831 Controls. DISEASE MARKERS 2018; 2018:3061974. [PMID: 30245752 PMCID: PMC6139213 DOI: 10.1155/2018/3061974] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Accepted: 07/25/2018] [Indexed: 12/31/2022]
Abstract
Manganese superoxide dismutase (MnSOD) plays a critical role in the defense against reactive oxygen species. The association between MnSOD Val16Ala polymorphism and cancer risk has been widely studied, but the results are contradictory. To obtain more precision on the association, we performed the current meta-analysis with 33,098 cases and 37,831 controls from 88 studies retrieved from PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of association. We found that the polymorphism was associated with an increased overall cancer risk (homozygous: OR = 1.09, 95% CI = 1.00-1.19; heterozygous: OR = 1.07, 95% CI = 1.02-1.12; dominant: OR = 1.08, 95% CI = 1.02-1.14; and allele comparison: OR = 1.06, 95% CI = 1.02-1.11). Stratification analysis further showed an increased risk for prostate cancer, Asians, Caucasians, population-based studies, hospital-based studies, low quality and high quality studies. However, the increased risk for MnSOD Val16Ala polymorphism among Asians needs further validation based on the false-positive report probability (FPRP) test. To summarize, this meta-analysis suggests that the MnSOD Val16Ala polymorphism is associated with significantly increased cancer risk, which needs further validation in single large studies.
Collapse
Affiliation(s)
- Ping Wang
- Department of Biochemistry and Molecular Biology, Medical College, Henan University of Science and Technology, Luoyang, Henan 471023, China
| | - Yanfeng Zhu
- School of Materials Science and Engineering, Henan University of Science and Technology, Luoyang, Henan 471023, China
| | - Shoumin Xi
- Department of Biochemistry and Molecular Biology, Medical College, Henan University of Science and Technology, Luoyang, Henan 471023, China
| | - Sanqiang Li
- Department of Biochemistry and Molecular Biology, Medical College, Henan University of Science and Technology, Luoyang, Henan 471023, China
| | - Yanle Zhang
- Department of Biochemistry and Molecular Biology, Medical College, Henan University of Science and Technology, Luoyang, Henan 471023, China
| |
Collapse
|